Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg StudyHenner Stege, Carmen Loquai, Elisabeth Livingstone et al.|Cancers|2021Cited by 23
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Carmen Loquai, Henner Stege et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 18
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Henner Stege, Jochen Utikal et al.|European Journal of Cancer|2025Cited by 4
459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREGMaximilian Haist, Carmen Loquai, Henner Stege et al.|Regular and Young Investigator Award Abstracts|2023Cited by 0